We are not hiding from anyone (rather difficult if you are a public company), we are just not actively promoting RAC to large pharma at the moment. We think returns to our shareholders will be maximised if we have clinical data of bisantrene efficacy in targeting FTO. Everyone is welcome to have a different opinion on this, but this is our considered opinion based on extensive consultation and discussion at the board level.
Ann: Race Strategic Update March 2021, page-431
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |